Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Size: px
Start display at page:

Download "Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression"

Transcription

1 SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version: 3 Date Approved: January 2013 Review Date: January 2015 Lithium for Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of Lithium can be shared between the specialist and general practitioner or non-medical prescriber in primary care (GP). GPs are invited to participate. If the GP is not confident to undertake these roles, then he or she is under no obligation to do so. In that case, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. If a specialist asks the GP to prescribe drugs for this treatment, the GP should reply to this request as soon as practicable. Sharing of care assumes communication between the specialist, GP and patient. The intention to share care should be explained to the patient by the doctor initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. For patients detained under The Mental Health (Care and Treatment) (Scotland) Act 2003, lithium must be included in the T2 or T3 Treatment Plan. Patients with bipolar disorder or treatment resistant depression are under regular specialist follow-up. This provides an opportunity to discuss and to monitor drug therapy. The doctor who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. Lithium is a well-established treatment for mood disorders including bipolar disorder, mania and recurrent or resistant depression it has a narrow therapeutic window and monitoring of blood levels is essential for its safe use. National Patient Safety Agency (NPSA) In December 2009 the NPSA made the following recommendations in a Patient Safety Alert Patients prescribed lithium are monitored in accordance with NICE guidance on the management of bipolar disorder There are reliable systems to ensure blood test results are communicated between laboratories and prescribers At the start of lithium therapy and throughout their treatment patients receive appropriate ongoing verbal and written information and a record book to track lithium blood levels and relevant clinical tests. Record book available from Clinical Management, Stratheden Hospital ( ). Prescribers and pharmacists check that blood tests are monitored regularly and that it is safe to issue a repeat prescription and/or dispense the prescribed lithium Systems are in place to identify and deal with medicines that might adversely interact with lithium therapy.

2 RESPONSIBILITIES and ROLES Specialist responsibilities 1 Confirm diagnosis 2 Assessment of baseline mental state 3 Discuss the benefits and side effects of treatment with the patient and advise patient of signs of toxicity. 4 For patients detained under The Mental Health (Care and Treatment) (Scotland) Act 2003, ensure that lithium is included in the T2 or T3 Treatment Plan. 5 Undertake baseline investigations- renal function, thyroid function, calcium and baseline ECG if existing cardiac disease or risk factors 6 Ensure that a baseline weight is recorded 7 Consider any drug interactions 8 Consider any pre-existing conditions which require particular caution with lithium 9 Discuss the shared care arrangement with the patient. 10 Provide patient with Lithium Therapy NPSA booklet [Record book available from Clinical Management, Stratheden Hospital ( )] and complete initial details. 11 Initiate treatment with Lithium or advise GP on initiating treatment. Prescribe using brand name, usually Priadel. 12 Ensure that serum lithium monitoring is carried out during initial titration and after dose changes either in secondary care or by arrangement with the GP 13 Counsel female patients to take contraceptive precautions during treatment. Record in GP referral letter that contraceptive advice has been given 14 Ask the GP whether he or she is willing to participate in shared care. 15 Complete Shared Care Lithium Treatment Plan 16 Review the patient's condition and monitor compliance and response to treatment regularly where indicated. The need for continued lithium therapy should be assessed regularly and patients should be maintained on lithium after 3-5 years only if benefit persists. 17 Advise GP of the necessary ongoing monitoring and the frequency. 18 Monitor any other parameters considered necessary, or advise GP on which to monitor. 19 Communicate promptly with the GP when treatment is changed or needs to be changed by the GP, any results of the monitoring undertaken, and assessment of adverse events. 20 Have a mechanism in place to receive rapid referral of a patient from the GP in the event of deteriorating clinical condition. 21 Evaluate any adverse events reported by patient, carer or GP 22 Report adverse events to the MHRA via Yellow Card Scheme. 23 Ensure that clear backup arrangements exist for GPs to obtain advice and support. General Practitioner responsibilities 1 Reply to the request for shared care as soon as practicable. 2 Prescribe Lithium at the dose recommended. Prescribe using brand name, usually Priadel 3 Adjust the dose as advised by the specialist. 4 Consider any drug interactions 5 Monitor Lithium serum levels, calcium, renal and thyroid function as in monitoring section 6 Monitor weight/bmi 7 Update Shared Care Treatment Plan 8 Confirm patient has NPSA booklet and update information 9 Report to and seek advice from the specialist on any aspect of patient care that is of concern and may affect treatment. 10 Refer patient to specialist if his or her condition deteriorates. 11 Stop treatment on the advice of the specialist or immediately if an urgent need to stop treatment arises. 12 Report adverse events to the specialist and to the MHRA via the Yellow Card Scheme. Patient's role 1 Attend regular appointments for assessment and blood sampling 2 Report to the specialist or GP if he or she does not have a clear understanding of the treatment. 3 Share any concerns in relation to treatment. 4 Report any adverse effects to the specialist or GP. 5 Ensure hand-held record in NPSA booklet is regularly updated

3 BACK-UP ADVICE AND SUPPORT Sector Consultant Psychiatrist Pharmacy Services or local clinical pharmacist SUPPORTING INFORMATION Licensed indications (From SPC Priadel- indications for other products may vary) Management of acute manic or hypomanic episodes Management of episodes of recurrent depressive disorders where treatment with other antidepressants has been unsuccessful Prophylaxis against bipolar affective disorders Control of aggressive behaviour or intentional self-harm Dosage and Administration Lithium has a low therapeutic/toxic ratio and should be started at a low dose and titrated up to achieve therapeutic levels as indicated by serum lithium monitoring. The recommended therapeutic range is mmol/L ( mmol/L in elderly patients). Dosage must be individualised depending on serum lithium levels and clinical response. The dosage necessary to maintain serum lithium levels within the therapeutic range varies from patient to patient. The minimum effective dose should be sought and maintained. Contraindications and precautions for use Contraindications Hypersensitivity to lithium or to any of the excipients; Cardiac disease. Cardiac insufficiency. Severe renal impairment. Untreated hypothyroidism. Breast-feeding. Patients with low body sodium levels, including for example dehydrated patients or those on low sodium diets. Addison's disease. Brugada syndrome or family history of Brugada syndrome. See SPC or BNF for complete list of precautions Pregnancy Lithium therapy should not be used during pregnancy, especially during the first trimester, unless considered essential. Women of child-bearing potential should use effective contraceptive methods during treatment with lithium Women taking lithium who are planning a pregnancy or who become pregnant must be referred to psychiatric services for advice. Breastfeeding Lithium is excreted in breast milk with resultant risk of toxicity in the infant. Manufacturers advise to avoid. Withdrawal Unless due to serious adverse reaction, withdrawal should be gradual and take place under the supervision of a Consultant in Psychiatry. Abrupt discontinuation increases the risk of relapse. See BNF section 4.2.3

4 Side Effects See SPC or BNF for complete list of adverse effects Side effects may be short term and are usually dose dependent. They can often be prevented or relieved by a moderate reduction in dose. Type of adverse effect GI disturbances e.g. nausea, diarrhoea, dry mouth Weight gain Oedema Fine tremor Polyuria (frequent urination) Polydipsia (frequent thirst) Hypothyroidism Signs of toxicity: Blurred vision, muscle weakness, drowsiness, coarse tremor, dysarthria, ataxia, confusion, convulsions, nausea & vomiting, ECG changes. Action to be taken Ensure patient aware of need for fluid replacement Monitor Advise to avoid crash diets & sugary drinks. Monitor may respond to dose reduction. Consider slight reduction in dose Advise re: fluid intake. May require investigation for diabetes insipidus if persistent Consider thyroid replacement if clinically indicated Stop lithium immediately, measure lithium, creatinine, urea and electrolytes. Refer to hospital if clinical condition warrants MONITORING Serum Lithium monitoring Serum lithium must be monitored 5-7 days after initiation, then weekly until steady state is reached, then 3 monthly when stable (more frequently, typically 2 monthly in the elderly). More frequent monitoring is required following alteration of dosage; on development of intercurrent disease; in those with or at risk of cardiac, renal or thyroid disease; signs of manic or depressive relapse; following significant change in sodium or fluid intake; if an interacting drug is being taken or if signs of lithium toxicity occur. Lithium serum levels should be measured 12 hours after the previous dose. Patients taking lithium once daily at night should have the level measured in the morning 12 hours after the previous night time dose. Patients taking lithium twice daily should have the level measured in the morning 12 hours after the previous night time dose. The morning dose must be postponed until after the sample has been taken. Cardiac, renal, thyroid and calcium monitoring- minimum requirements Baseline ECG for those with existing cardiac disease or risk factors. Renal function- baseline and then every 6 months. Calcium- baseline and then every 6 months Thyroid function -TSH and T4 baseline and then every 6 months More frequent monitoring may be indicated in those with or at risk of cardiac, renal or thyroid disease. Weight should also be monitored Drug Interactions Refer to SPC or BNF appendix 1 for complete list Some medicines may result in increased lithium levels and risk of toxicity, e.g. diuretics (especially thiazides), NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, SSRIs and other psychotropic medicines. Increased risk of ventricular arrhythmias with amiodaraone (avoid). Cost REFERENCES Priadel Tablets 200mg 100 tablets 2.30 Priadel Tablets 400mg 100 tablets 3.35 Priadel Liquid 150ml 5.61 BNF Edition 63 March 2012 NICE Clinical Guideline 38 Bipolar Disorder 2006 SIGN Guideline 82 Bipolar Affective Disorder 2005

5 ADDITIONAL INFORMATION Preparations are NOT Bioequivalent Two salts of lithium are available (lithium carbonate and lithium citrate) which contain different amounts of lithium (mmolli + ) and are not interchangeable. Lithium carbonate (tablets) 200mg lithium citrate (liquids) 509mg Lithium must always be prescribed by trade name Priadel tablets are the most frequently prescribed lithium preparation in Fife and Priadel liquid the most commonly prescribed liquid lithium preparation. *See Appendix 1- Equivalent doses of Priadel liquid and Priadel tablets. Alternative preparations Lithium preparations vary widely in bioavailability therefore any change of preparation (even those containing the same salt) requires the same precautions as initiation of treatment i.e. weekly monitoring. LITHIUM CARBONATE TABLETS Trade Name Tablet Strength Available Amount of Lithium (Li + ) Priadel 200mg m/r (scored) 400mg m/r (scored) 5.4mmol/200mg 10.8mmol/400mg Camcolit 250 Camcolit mg (scored) 400mg m/r (scored) 6.8mmol/250mg 10.8mmol/400mg Liskonum 450mg m/r (scored) 12.2mmol/450mg LITHIUM CITRATE LIQUID Trade Name Liquid Strength Available Amount of Lithium (Li + ) Priadel * 520mg/5ml 5.4mmol/5ml Li-liquid 509mg/5ml 5.4mmol/5ml Li-liquid 1018mg/5ml 10.8mmmol/5ml Dosing frequency depends on preparation prescribed Liquid preparations and Liskonum tablets should be prescribed twice daily Other lithium preparations are usually prescribed as a single dose at night. Interpretation of serum lithium level (Range: mmol/L, elderly mmol/L) Level Action to Be Taken < 0.5mmol/L & patient is well and pattern Do not alter dose. of levels has been low but within specified range for that patient. < 0.5mmol/L & patient unwell & pattern of Assess compliance, increase dose if appropriate, and recheck levels on lower end of specified range for level in 5 days. that patient. < 0.5mmol/L & is inconsistent with the Assess compliance, consider other factors e.g. drug interactions, trend. excess fluid intake, brand change, and recheck level. > 1.0mmol/L with no signs of toxicity. If there is an explanation for the high level e.g. dehydration, timing of level, interacting medicines, brand change, correct where possible and recheck level. > 1.0mmol/L with no signs of toxicity and Decrease dose, encourage fluids, recheck in 5 days. the trend is for high end of range. > 1.0mmol/L with no signs of toxicity and Recheck level, check e GFR, and urea, creatinine and no explanation for high level. If patient shows signs of toxicity Blurred vision, muscle weakness, drowsiness, coarse tremor, dysarthria, ataxia, confusion, convulsions, nausea & vomiting, ECG changes electrolytes. Stop lithium immediately, measure lithium, egfr, creatinine, urea and electrolytes. Refer to hospital if clinical condition warrants

6 Appendix 1 Equivalent doses of Priadel Liquid and Priadel Tablets All liquid lithium preparations contain Lithium Citrate and all tablet preparations contain Lithium Carbonate. These are not interchangeable. Priadel is the most frequently prescribed brand of lithium in Fife. Each 5ml of Priadel liquid contains 520mg of lithium citrate which is equivalent to 204mg of lithium carbonate. Priadel Tablets contain lithium carbonate. Confusion between Lithium Carbonate and Lithium Citrate is a common cause of error. Equivalent doses of Priadel tablets and liquid Priadel Tablets Priadel Liquid 200mg 5ml 400mg 10ml 600mg 15ml 800mg 20ml 1g 25ml 1.2g 30ml 1.4g 35ml Priadel liquid should be given in divided doses, ideally twice daily The following table shows what quantity of Priadel liquid should be prescribed if switching between Priadel l tablets and Priadel liquid. Priadel tablets Priadel liquid 200mg daily 2.5ml twice daily 400mg daily 5ml twice daily 600mg daily 7.5ml twice daily 800mg daily 10ml twice daily 1g daily 12.5ml twice daily 1.2g daily 15ml twice daily 1.4g daily 17.5ml twice daily All Lithium preparations must be prescribed by brand name (usually Priadel ) as bioavailability varies. Any change in formulation (e.g. tablets to liquid) or brand requires the same monitoring of lithium levels as initiation of treatment If there are any queries about changing between the different preparations of Priadel or any of the other lithium preparations please contact your local clinical pharmacist for advice or alternatively contact pharmacy services on

7 SHARED CARE LITHIUM TREATMENT PLAN PATIENT SPECIFIC DETAILS CONSULTANT To be completed at time of discharge/outpatient review and sent to GP NAME ADDRESS DOB/CHI Current indication: (e.g.bipolar prophylaxis / augmentation) Desired Therapeutic range: ( mmol/L, elderly mmol/L) Dosage Regime: Brand used: Last level/date: / Level next due: PHYSICAL & BLOOD MONITORING TO BE CARRIED OUT BY: Psychiatrist Lithium Clinic Day Care Unit GP Other Frequency of lithium monitoring (minimum 3 monthly/2 monthly in elderly) Completed by (sign & print name) MINIMUM MONITORING REQUIREMENTS FOR ESTABLISHED LITHIUM TREATMENT Date NB more frequent monitoring may be required if clinical indications arise and in higher risk patients, e.g. those on interacting drugs (see BNF), those with or at risk of renal / thyroid / cardiac disease. BASELINE ECG DONE? Yes/No/Not required LITHIUM minimum 3 monthly NB sample at approx. 12 hours post dose. Ensure time interval is same at each measurement, if varies, state clearly on form. RENAL AND THYROID FUNCTION CALCIUM 6 monthly 6 monthly PSYCHIATRIC REVIEW GP s should consider patients for formal review by psychiatrist after 2 5 years of lithium therapy to assess ongoing benefit.

8 Results Current dose regimen and Brand Date of next blood level Date of current blood level Serum Lithium Level (mmol/l) Renal function (egfr) Thyroid function Calcium Weight/ BMI Comments e.g. dose alteration, side effects, mood rating, non-compliance

Essential Shared Care Agreement: Lithium

Essential Shared Care Agreement: Lithium Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed

More information

Lithium Shared Care Protocol and Information for Oxfordshire GPs

Lithium Shared Care Protocol and Information for Oxfordshire GPs Summary Lithium Shared Care Protocol and Information for Oxfordshire GPs 1. Lithium is predominantly used in the following situations: a. The acute treatment of mania b. Prophylaxis in bipolar disorder

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol NHS North Somerset NHS South Gloucestershire North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please complete

More information

Lithium continuing care guideline summary (refer to full guidelines for further information)

Lithium continuing care guideline summary (refer to full guidelines for further information) Lithium continuing care guideline summary (refer to full guidelines for further information) Formulary status YELLOW: Specialist initiation with GPs continuing care once patients are on a stable dose Lithium

More information

Formulary and Prescribing Guidelines

Formulary and Prescribing Guidelines Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary

More information

SHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance

SHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance SHARED CARE GUIDELINE FOR LITHIUM 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of lithium.

More information

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing

More information

NPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE

NPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE NPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE Implementation Date Spring 2013 Review Date Spring 2016 NPSA Safer Lithium Therapy Guidelines for NHS Lanarkshire BACKGROUND On 1 st December 2009

More information

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Monitoring of patients prescribed lithium

Monitoring of patients prescribed lithium POMH-UK Topic 7 Monitoring of patients prescribed lithium Please use the following to cite this report: Prescribing Observatory for Mental Health (2009). Topic 7 baseline report. Monitoring of patients

More information

Lithium Good Practice Standards

Lithium Good Practice Standards Lithium Good Practice Standards Safe Lithium Treatment Scope This document is intended to support the safe use of lithium in mental health services including Forensic and Learning Disability services across

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

Shared Care Guideline Metolazone for fluid management in CKD (Adults)

Shared Care Guideline Metolazone for fluid management in CKD (Adults) Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility

More information

EFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP.

EFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. The aim of an Effective Shared Care Agreement

More information

Mental Health Medicines Management Pilot. Community Pharmacy Lithium Support Service Guidance

Mental Health Medicines Management Pilot. Community Pharmacy Lithium Support Service Guidance Mental Health Medicines Management Pilot Community Pharmacy Lithium Support Service Guidance Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact Aaron Coulter Group / Committee

More information

AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE

AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE Effective Shared Care Agreement (ESCA) Midodrine ESCA: For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment

More information

Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM

Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM Directorate of Chief Medical Officer T: 0131-244 6930 E: john.mitchell4@gov.scot Dear Colleagues, NATIONAL STANDARD FOR MONITORING THE PHYSICAL HEALTH OF PEOPLE BEING TREATED WITH LITHIUM Lithium is a

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158

More information

Hertfordshire shared care protocol January 2018

Hertfordshire shared care protocol January 2018 Hertfordshire shared care protocol January 2018 Safe Use of Lithium in Adults Version 1.1 Shared Care Guideline This protocol provides prescribing and monitoring guidance for lithium therapy. It should

More information

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date: Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to

More information

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to

More information

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

More information

Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis

Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy

More information

NHS GG&C -Mental Health Services. Lithium Ward Bundle

NHS GG&C -Mental Health Services. Lithium Ward Bundle Lithium Ward Bundle Lithium is a useful drug, particularly in the maintenance treatment of bipolar affective disorder, recurrent depression and self injurious behaviour. It is widely used and most patients

More information

POMH-UK QUALITY IMPROVEMENT PROGRAMME LITHIUM MONITORING. Thomas R. E. Barnes

POMH-UK QUALITY IMPROVEMENT PROGRAMME LITHIUM MONITORING. Thomas R. E. Barnes POMH-UK QUALITY IMPROVEMENT PROGRAMME LITHIUM MONITORING Thomas R. E. Barnes LITHIUM Evidence-based guidelines support the use of lithium in the prophylaxis of bipolar disorder, protecting against both

More information

SULFASALAZINE (Adults)

SULFASALAZINE (Adults) Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn

More information

Lithium Prescribing and Monitoring Guidelines

Lithium Prescribing and Monitoring Guidelines Lithium Prescribing and Monitoring Guidelines When using this document please ensure that the version you are using is the most up to date either by checking on the Trust intranet or if the review date

More information

Information leaflet for primary care: Agomelatine

Information leaflet for primary care: Agomelatine Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin

More information

. AREAS OF RESPONSIBILITY FOR SHARED CARE

. AREAS OF RESPONSIBILITY FOR SHARED CARE SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the

More information

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus. Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION

More information

Shared Care Guideline for Olanzapine (Zyprexa )

Shared Care Guideline for Olanzapine (Zyprexa ) Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the

More information

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

SHARED CARE AGREEMENT: MELATONIN (CHILDREN) NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate

More information

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011 POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

Guidelines for the Management of Patients on Lithium

Guidelines for the Management of Patients on Lithium Guidelines for the Management of Patients on Lithium Review Date: September 2011 Introduction These guidelines have been developed by a multidisciplinary team to ensure a safe, effective and consistent

More information

Gwent Shared Care Protocol LITHIUM (BNF section 4.2.3) for all licensed indications (see section 1 below)

Gwent Shared Care Protocol LITHIUM (BNF section 4.2.3) for all licensed indications (see section 1 below) Gwent Shared Care Protocol LITHIUM (BNF section 4.2.3) for all licensed indications (see section 1 below) Protocol No. 22 General guidance 1. Licensed indication 2. Therapeutic use & Background information

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER

More information

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the

More information

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on

More information

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a

More information

Tacrolimus (Adoport, Prograf, Modigraf or Advagraf )

Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) Shared Care Guideline DRUG: Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) for Renal Transplant (Adults) Introduction: Indication: Prophylaxis of transplant rejection in kidney recipients Tacrolimus

More information

Procedure Reviewed By: Narinder Sangha Deputy Chief Pharmacist STANDARD OPERATING PROCEDURE

Procedure Reviewed By: Narinder Sangha Deputy Chief Pharmacist STANDARD OPERATING PROCEDURE Written By: Objective By: ed By: To ensure safe and consistent working practice throughout Black Country Partnership Foundation Trust (BCPFT) and to avoid unnecessary harm to patients on lithium therapy

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults

Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:

More information

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) CP11 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION The

More information

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines

More information

lithium record book This record book contains information that will also be held in your patient records.

lithium record book This record book contains information that will also be held in your patient records. lithium record book This record book contains information that will also be held in your patient records. lithium record book This record book contains information that will also be held in your patient

More information

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1

More information

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately

More information

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )

Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities

More information

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD

More information

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease

More information

Shared Care Guidance. Vigabatrin

Shared Care Guidance. Vigabatrin North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.

More information

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and

More information

SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults

SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation

More information

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document

More information

Depression: selective serotonin reuptake inhibitors

Depression: selective serotonin reuptake inhibitors Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

Lithium Therapy. Record book

Lithium Therapy. Record book Lithium Therapy Record book Record book This record book contains information that will also be held in your patient record. Take this record book with you each time you: - see your GP; - attend a clinic;

More information

Azathioprine Shared Care Guideline for GPs

Azathioprine Shared Care Guideline for GPs Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis

More information

SHARED CARE AGREEMENT: METHOTREXATE S/C

SHARED CARE AGREEMENT: METHOTREXATE S/C NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx

More information

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an

More information

MELATONIN Insomnia and Sleep Disorders in Children

MELATONIN Insomnia and Sleep Disorders in Children DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which

More information

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be

More information

HYDROXYCARBAMIDE for Haematological conditions (Adults)

HYDROXYCARBAMIDE for Haematological conditions (Adults) Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological

More information

Essential Shared Care Agreement Naltrexone

Essential Shared Care Agreement Naltrexone In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy

More information

The doctor/nmp who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use.

The doctor/nmp who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. The 3T s Formulary NHS Swindon, NHS Wiltshire Great Western Hospitals NHS Foundation Trust (In collaboration with Avon and Wiltshire Mental Health Partnership and Oxford Health NHS Foundation Trust) Shared

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection. `Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob

More information

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Liothyronine for treatment resistant depression

Liothyronine for treatment resistant depression DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK Liothyronine for treatment resistant depression 1. REFERRAL CRITERIA Shared Care is only appropriate if it provides the

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE (Approved May 2014 - Review Date May 2016) GENERAL POLICY PATIENT GROUP DIRECTION

More information

Bipolar Affective Disorder Formulary Guidance [3] (adapted from NICE guideline CG185)

Bipolar Affective Disorder Formulary Guidance [3] (adapted from NICE guideline CG185) Bipolar Affective Disorder Formulary Guidance [3] (adapted from NICE guideline CG185) 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable

More information

APOMORPHINE (Adults) Shared Care Guidelines DRUG:

APOMORPHINE (Adults) Shared Care Guidelines DRUG: Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information